{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T01:49:43Z","timestamp":1791769783944,"version":"4.3.4"},"reference-count":21,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T00:00:00Z","timestamp":1566518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Spero Therapeutics"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:p>SPR741 is a novel polymyxin B derivative, with minimal intrinsic antibacterial activity and reduced nonclinical nephrotoxicity compared to levels with polymyxin B, that interacts with the outer membrane of Gram-negative bacteria, enhancing penetration of coadministered antibiotics.<\/jats:p>","DOI":"10.1128\/aac.00892-19","type":"journal-article","created":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T06:33:43Z","timestamp":1561962823000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":54,"title":["Safety, Tolerability, Pharmacokinetics, and Drug Interaction Potential of SPR741, an Intravenous Potentiator, after Single and Multiple Ascending Doses and When Combined with \u03b2-Lactam Antibiotics in Healthy Subjects"],"prefix":"10.1128","volume":"63","author":[{"given":"Paul B.","family":"Eckburg","sequence":"first","affiliation":[{"name":"Spero Therapeutics, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy","family":"Lister","sequence":"additional","affiliation":[{"name":"Spero Therapeutics, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susannah","family":"Walpole","sequence":"additional","affiliation":[{"name":"Spero Therapeutics, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Keutzer","sequence":"additional","affiliation":[{"name":"Spero Therapeutics, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Utley","sequence":"additional","affiliation":[{"name":"Spero Therapeutics, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Tomayko","sequence":"additional","affiliation":[{"name":"Pfizer, Inc., New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Kopp","sequence":"additional","affiliation":[{"name":"E. Sullivan and Associates, LLC, Newburyport, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Farinola","sequence":"additional","affiliation":[{"name":"CMAX Clinical Research and Department of Clinical Pharmacology, Royal Adelaide Hospital, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Coleman","sequence":"additional","affiliation":[{"name":"Acceleron Pharma, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","unstructured":"CDC. 2010. Healthcare-associated infections: Acinetobacter in healthcare settings. http:\/\/www.cdc.gov\/HAI\/organisms\/acinetobacter.html."},{"key":"e_1_3_2_3_2","unstructured":"WHO. 2018. Antibiotic resistance fact sheet. http:\/\/www.who.int\/mediacentre\/factsheets\/antibiotic-resistance\/en\/."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.5694\/mja14.01257"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw282"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.ARBA-0007-2017"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2016.09.002"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-018-0388-z"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00200-17"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01439-09"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt039"},{"key":"e_1_3_2_12_2","unstructured":"Mendes RE Rhomberg PR Lister T Cotroneo N Rubio A Flamm R. 2018. Antimicrobial activity of ceftazidime and piperacillin-tazobactam tested in combination with a potentiator molecule (SPR741) against Enterobacteriaceae causing urinary-tract infections poster P1671. 28th Eur Congress Clin Microbiol Infect Dis Madrid Spain 21 to 24 April 2018."},{"key":"e_1_3_2_13_2","unstructured":"Mendes RE Rhomberg PR Lister T Cotroneo N Rubio A Flamm R. 2018. Evaluation of synergistic effects of a potentiator molecule (SPR741) when tested in combination with a series of beta-lactam agents against a challenge set of Gram-negative pathogens poster P1672. 28th Eur Congress Clin Microbiol Infect Dis Madrid Spain 21 to 24 April 2018."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00239-18"},{"key":"e_1_3_2_15_2","unstructured":"VanScoy BD Rubio A Fikes S Conde H Lakota EA George DR Utley LJ Lister T Bhavnani SM Parr TR Ambrose PG. 2018. A pharmacokinetics-pharmacodynamic evaluation of the novel antibiotic potentiator SPR741 in combination with piperacillin\/tazobactam against Enterobacteriaceae asbstr 594. ASM Microbe 2018."},{"key":"e_1_3_2_16_2","unstructured":"Zou Y Cotroneo N Lister T Rubio A. 2018. Bactericidal activity of ceftazidime in combination with SPR741 against susceptible extended-spectrum beta-lactamase producing and multi-drug resistant Escherichia coli Klebsiella pneumoniae and Enterobacter species poster P1674. 28th Eur Congress Clin Microbiol Infect Dis Madrid Spain 21 to 24 April 2018."},{"key":"e_1_3_2_17_2","unstructured":"Zou Y Cotroneo N Lister T Rubio A. 2018. Bactericidal activity of piperacillin-tazobactam in combination with SPR741 against susceptible extended-spectrum beta-lactamase producing and multi-drug resistant Escherichia coli Klebsiella pneumoniae and Enterobacter species poster P1675. 28th Eur Congress Clin Microbiol Infect Dis Madrid Spain 21 to 24 April 2018."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01239-17"},{"key":"e_1_3_2_19_2","unstructured":"Citron DM Tyrrell KL Rubio A Goldstein EJC. 2018. In vitro activity of ceftazidime alone and in combination with SPR741 against anaerobic bacteria abstr 2287. 28th Eur Congress Clin Microbiol Infect Dis Madrid Spain 21 to 24 April 2018."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2015.05.008"},{"key":"e_1_3_2_21_2","first-page":"442","article-title":"Antibiotic interactions: answers to 4 common questions","volume":"65","author":"Onysko M","year":"2016","unstructured":"Onysko M, Holcomb N, Hornecker J. 2016. Antibiotic interactions: answers to 4 common questions. J Fam Pract 65:442\u2013448.","journal-title":"J Fam Pract"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy378"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00892-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00892-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:22:44Z","timestamp":1645460564000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00892-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1128\/AAC.00892-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.00892-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"2019-04-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00892-19"}}